A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

Study Identifier:
VS-7375-201
CT.gov Identifier:
NCT07644559
EudraCT Identifier:
N/A
EU Trial (CTIS) Number:
N/A
Study Contact Information:
N/A
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
N/A
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
Phase II
Sex
Female & Male
Age
18+ years
Study Drug
Drug: EXPERIMENTAL: VS-7375 + cetuximab 1L PDAC
Read More
Drug: Drug: cetuximab
Drug: Subcutaneous infusion
Drug: Drug: VS-7375
Drug: Taken by mouth
Drug: EXPERIMENTAL: VS-7375 + cetuximab 2L PDAC
Drug: EXPERIMENTAL: VS-7375 Monotherapy
Study Status
Indicates the current recruitment status or the expanded access status
Recruiting

Requirements information
Inclusion criteria
  • * Histopathology confirmed PDAC
  • * Measurable disease per RECIST 1.1
  • * Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
  • * ECOG PS=0 or 1
  • Adequate organ function
  • VS-7375 + cetuximab (2L PDAC) :
  • -Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months
  • VS-7375 + cetuximab (1L PDAC) :
  • -Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease
Exclusion criteria
  • Have any other documented co-existing common RAS mutation(s)
  • * Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
  • * Major surgery within 4 weeks of first treatment dose
  • * Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose
  • * History of drug-induced Interstitial Lung Disease
  • * Receipt of prior direct RAS inhibitor
  • * Untreated or symptomatic CNS metastasis
  • * Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
  • * Receipt of PPI or H2 blocker within 5 days
  • * Inability to swallow oral medication
  • * Other protocol-defined inclusion/exclusion criteria may apply

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

View Study Information

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START Dallas Fort Worth
Fort Worth, TX, United States, 76104
Investigator
Salwan Al Mutar
Status
Recruiting
Condition(s) Treated at Site
Location
START Los Angeles
Los Angeles, CA, United States, 90025
Investigator
Navid Hafez
Status
Recruiting
Condition(s) Treated at Site
Location
START Midwest
Grand Rapids, MI, United States, 49546
Investigator
Sreenivasa Chandana
Status
Recruiting
Condition(s) Treated at Site
Location
START Mountain Region
West Valley City, UT, United States, 84119
Investigator
William McKean
Status
Recruiting
Condition(s) Treated at Site
Location
START New Jersey
East Brunswick, NJ, United States, 08816
Investigator
Bruno Fang
Status
Recruiting
Condition(s) Treated at Site
Location
START San Antonio
San Antonio, TX, United States, 78229
Investigator
Drew Rasco
Status
Recruiting
Condition(s) Treated at Site